Nippon Shinyaku Co., Ltd. announced that it has obtained approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for Uptravi tablets 0.2 mg and 0.4… read more.
Merck Inc.,( known as MSD outside of the United States and Canada), announced positive topline results from the Phase III ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Yuvanci, intended for the… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of a single… read more.
Liquidia Corporation has announced that the FDA granted tentative approval for Yutrepia (treprostinil) inhalation powder, previously referred to as LIQ 861. Yutrepia is indicated for the treatment of… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved Uptravi (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension… read more.
Findings from an analysis of the first 500 patients enrolled in the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry) found more than three-quarters (76%) of pulmonary arterial hypertension… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
